Skip to main
ASPI

ASPI Stock Forecast & Price Target

ASPI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ASP Isotopes is positioning itself for significant revenue growth by 2026 through expansions in nuclear medicine, quantum technology, and diversified geographical operations. Furthermore, their partnership with the South African Nuclear Energy and funding from the U.S. DOE demonstrate strong support for their unique and valuable position as the sole commercial provider of highly-enriched isotopes. Challenges with infrastructure and operational execution may pose short-term obstacles, but the recent hint of increased revenue suggests that the company is taking proactive steps to address these issues under new leadership.

Bears say

ASP Isotopes is a relatively new company, with promising technologies for isotope enrichment that could give it a competitive advantage in the medical, semiconductor, and nuclear industries. However, the company is still in the development stage and faces risks related to scaling production, securing regulatory approvals and permits, and managing its financing and debt. Additionally, there are concerns about political risks in South Africa, where the company does a significant amount of its operations. Proving the scalability and effectiveness of their technologies, as well as securing long-term contracts, will be key for the company's success in the future.

ASPI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ASP Isotopes Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ASP Isotopes Inc (ASPI) Forecast

Analysts have given ASPI a Buy based on their latest research and market trends.

According to 2 analysts, ASPI has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ASP Isotopes Inc (ASPI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.